ASPH and acute myeloid leukemia: Importantly, unlike data in solid tumors that suggest the role of ASPH as a predictive marker of poor clinical prognosis (17–19), we found that ASPH status was not associated with clinical outcomes (CR, EFS, OS) in AML.